Natalizumab in pediatric multiple sclerosis patients
Pediatric multiple sclerosis (MS) comprises 2-5% of all cases of MS. Although first-line disease-modifying therapy (DMT) including interferons and glatiramer acetate appear to be well tolerated in this population, recent work has suggested that a growing number of children suffer from disease which...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2010-09-01
|
| Series: | Therapeutic Advances in Neurological Disorders |
| Online Access: | https://doi.org/10.1177/1756285610381526 |
| _version_ | 1818335088772907008 |
|---|---|
| author | E. Ann Yeh Bianca Weinstock-Guttman |
| author_facet | E. Ann Yeh Bianca Weinstock-Guttman |
| author_sort | E. Ann Yeh |
| collection | DOAJ |
| description | Pediatric multiple sclerosis (MS) comprises 2-5% of all cases of MS. Although first-line disease-modifying therapy (DMT) including interferons and glatiramer acetate appear to be well tolerated in this population, recent work has suggested that a growing number of children suffer from disease which is resistant to treatment with these therapies. Natalizumab is a therapy which, although associated with a 1 : 1000 risk for progressive multifocal leukoencephalopathy (PML), has been shown to be well tolerated in the adult population and may lead to disease remission in adults with highly active disease. Reports of use of this therapy in the pediatric population with highly active disease have been published. This paper reviews current experience with the use of natalizumab in the pediatric MS population, with attention to potential risks and possible long-term outcomes in this population. |
| first_indexed | 2024-12-13T14:17:52Z |
| format | Article |
| id | doaj.art-3128e0f4db044c1ea453264793ad43b0 |
| institution | Directory Open Access Journal |
| issn | 1756-2856 |
| language | English |
| last_indexed | 2024-12-13T14:17:52Z |
| publishDate | 2010-09-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Neurological Disorders |
| spelling | doaj.art-3128e0f4db044c1ea453264793ad43b02022-12-21T23:42:12ZengSAGE PublishingTherapeutic Advances in Neurological Disorders1756-28562010-09-01310.1177/1756285610381526Natalizumab in pediatric multiple sclerosis patientsE. Ann YehBianca Weinstock-GuttmanPediatric multiple sclerosis (MS) comprises 2-5% of all cases of MS. Although first-line disease-modifying therapy (DMT) including interferons and glatiramer acetate appear to be well tolerated in this population, recent work has suggested that a growing number of children suffer from disease which is resistant to treatment with these therapies. Natalizumab is a therapy which, although associated with a 1 : 1000 risk for progressive multifocal leukoencephalopathy (PML), has been shown to be well tolerated in the adult population and may lead to disease remission in adults with highly active disease. Reports of use of this therapy in the pediatric population with highly active disease have been published. This paper reviews current experience with the use of natalizumab in the pediatric MS population, with attention to potential risks and possible long-term outcomes in this population.https://doi.org/10.1177/1756285610381526 |
| spellingShingle | E. Ann Yeh Bianca Weinstock-Guttman Natalizumab in pediatric multiple sclerosis patients Therapeutic Advances in Neurological Disorders |
| title | Natalizumab in pediatric multiple sclerosis patients |
| title_full | Natalizumab in pediatric multiple sclerosis patients |
| title_fullStr | Natalizumab in pediatric multiple sclerosis patients |
| title_full_unstemmed | Natalizumab in pediatric multiple sclerosis patients |
| title_short | Natalizumab in pediatric multiple sclerosis patients |
| title_sort | natalizumab in pediatric multiple sclerosis patients |
| url | https://doi.org/10.1177/1756285610381526 |
| work_keys_str_mv | AT eannyeh natalizumabinpediatricmultiplesclerosispatients AT biancaweinstockguttman natalizumabinpediatricmultiplesclerosispatients |